Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the ...

Guardant Health (NASDAQ:GH – Get Free Report) had its target price upped by Piper Sandler from $34.00 to $50.00 in a report ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The ...

Guardant Health (NASDAQ:GH – Get Free Report) had its target price boosted by research analysts at The Goldman Sachs Group ...

The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift toward multi-cancer detection.

Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...